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T cell immunoglobulin and mucin domain-1 (Tim-1) is expressed by CD4+ T cells, 
invariant natural killer T (iNKT) cells, and regulatory B cells (Bregs). Tim-1 expression 
on CD4+ T cells and iNKT cells typically promote proinflammatory responses, while   
Tim-1-expressing Bregs are immunosuppressive. However, the potential role of Tim-1 in 
anti-tumour immunity is unclear. To investigate the effects of Tim-1 on B16F1 melanoma 
and MC38 colorectal adenocarcinoma models, I compared tumour growth and survival 
between Tim-1-expressing (wild-type) and Tim-1-deficient mice. Using B16F1 melanoma, 
I demonstrated that Tim-1-deficient mice exhibited delayed tumour growth and improved 
survival, compared to wild-type mice. When immunized with heat-killed B16F1 melanoma 
cells, decreased frequencies of Bregs were found in Tim-1-deficient mice. These data 
suggest that Tim-1 expression may promote tumour growth by inducing Bregs. Therefore, 
anti-cancer treatments aimed at suppressing the function of Tim-1-expressing Bregs may 







Cancer is a disorder that describes abnormal cell growth or tumours that can interfere with 
the growth and development of normal cells. The high prevalence and mortality rate of 
cancer makes it a serious global burden. Throughout the years, various therapies have been 
developed to treat cancer, but curative therapies remain elusive for most cancers, including 
colon cancer and melanoma (skin cancer).  
The immune system plays a key role in detecting and eliminating cancer throughout life. 
Developing immunity against cancer (anti-cancer immunity), much like immunity against 
viruses, has the potential to be curative. While immune cells utilize a variety of 
mechanisms to kill cancer cells, the existence of cancer cells indicates that cancer cells 
learn to evade the host’s immune system. Cancer cells can escape the immune system by 
preventing detection or infiltration of immune cells, or by inhibiting the function of 
immune cells that have infiltrated the tumour. In addition, cancer cells can recruit immune 
cells that modulate and suppresses the immune system. Therefore, further understanding 
the workings of anti-cancer immunity may lead to potentially curative cancer therapies.  
This study focuses on T cell immunoglobulin and mucin domain-1 (Tim-1). Tim-1 is a 
protein found in some important anti-cancer immune cells. However, the role of Tim-1 in 
anti-cancer immune responses is unclear. 
In this study, I tested the effect of host Tim-1 on cancer growth and survival by implanting 
mouse colon or melanoma tumours into normal mice or mice lacking the gene for Tim-1. 
I found that mice lacking the Tim-1 gene have improved survival and delayed tumour 
growth, compared to mice expressing the Tim-1 gene. As well, examination of anti-cancer 
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immune responses in the mice lacking Tim-1 revealed that they have fewer B cells, a type 
of immune cell. I conclude that host Tim-1 impairs anti-cancer immune responses. 
Furthermore, the inhibition of host Tim-1 on B cells may be a new strategy for improving 
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Cancer is described as a disorder that results from genetic mutations or epigenetic 
alterations leading to aberrant cell growth. The high prevalence and mortality rate of cancer 
has made it an enormous global burden throughout the years. Cancer is the second leading 
cause of death in the world, with approximately one in six deaths being attributed to cancer 
[1, 2]. While innumerable efforts have been made to improve cancer therapies, the severity 
of this disease remains, and an effective solution remains elusive.  
1.2 The Immune System and Cancer 
The immune system is essential in recognizing and eradicating tumours. Tumour cells can 
lack ‘self’ molecules, such as MHC class I, or express neoantigens (new antigens formed 
as a result of tumour mutations that are not recognized by the immune system), and the 
immune system detects these abnormal cells as ‘non-self’ [3]. Subsequently, the immune 
system employs various cell types and mechanisms to eliminate tumour cells.  Some key 
players in anti-tumour immunity include T cells, Natural Killer (NK) cells, invariant 
natural killer T (iNKT) cells, and B cells [4-8].  
1.2.1 CD8+ T cells 
T cells are a vital component of the adaptive immune system, and T cells can develop into 
CD8+ T cells or CD4+ T cells. CD8+ T cells are cytotoxic lymphocytes restricted to 
recognizing antigens presented on major histocompatibility complex (MHC) class I 
molecules expressed by antigen presenting cells (APCs). Once activated by antigen-
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specific recognition, CD8+ T cells clonally expand into cytotoxic effector cells. Cytotoxic 
effects of CD8+ T cells are predominantly mediated by the release of perforin and 
granzyme, which are cytotoxins that trigger apoptosis in target cells, including susceptible 
tumour cells [5, 9]. Perforin functions to create pores in the cytoplasmic membrane of the 
target cell, allowing granzyme to enter the cell and activate apoptosis.  
In addition to its cytotoxic effects, CD8+ T cells enhance anti-tumour immune responses 
through cytokine functions. CD8+ T cells  produce the proteins tumour necrosis factor 
(TNF)-α and TNF-related apoptosis inducing ligand (TRAIL), which induces apoptosis in 
tumour cells [5, 6]. TNF is a highly pleiotropic cytokine and plays various roles in tumour 
immunosurveillance. The effects of TNF include apoptosis, necrosis, immune cell 
activation, cell migration, and even angiogenesis. As a result, TNF may promote tumour 
killing or tumour progression [10]. CD8+ T cells also produce IFN-γ to promote the 
activation and recruitment of NK cells, macrophages, and neutrophils [11]. IFN-γ can 
enhance the expression of MHC class I antigens by tumour cells, which improves detection 
and killing by CD8+ T cells [12]. Finally, IFN-γ can potentially act directly on tumour cells 
to inhibit growth [11]. To highlight the importance of IFN-γ in anti-tumour immune 
responses, a landmark study by Kaplan, et al.  demonstrated that IFN-γ receptor-deficient 
mice are prone to accelerated tumour growth when compared to wild-type mice, in both 
chemically-induced and spontaneous tumour models [13]. These data serve to emphasize 
the critical role of CD8+ T cells in anti-tumour immunity. 
1.2.2 CD4+ T cells 
While CD8+ T cells recognize antigens presented on MHC class I molecules and directly 
target tumours, CD4+ T cells are restricted to recognizing antigens presented on MHC 
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class II molecules by APCs. CD4+ T cells further develop into specific T helper (Th) 
subsets, including Th1, Th2, Th17, and regulatory T cells (Tregs). Th1 cells typically 
promote immune responses against intracellular pathogens, while Th2 cells generate 
immune responses against extracellular pathogens and may be implicated in promoting 
allergic responses. Studies have suggested that Th1 cells can play a role in anti-tumour 
immune responses by priming CD8+ T cells, recruiting NK cells, and inhibiting 
angiogenesis [7]. On the other hand, Th2 cells may function to promote or inhibit tumour 
growth [14]. The production of IL-4 by Th2 cells has been observed to recruit immune 
cells to the tumour, and the adoptive transfer of Th2 cells promotes the elimination of 
cytotoxic T lymphocyte resistant-melanoma in mice [7, 14]. In contrast, IL-5-producing 
Th2 cells were associated with progressive tumour growth in renal cell carcinoma and 
melanoma in humans [7, 15]. Similarly, Th17 cells, which promote immune responses 
against extracellular bacteria and fungi, can play a contradicting role in anti-tumour 
immune responses. In some tumour studies, the cytokine production by Th17 cells was 
correlated with tumour progression and angiogenesis [7, 16], while other studies have 
shown that the transfer of Th17 cells is associated with enhanced CD8+ T cell activation 
and immune cell recruitment to the tumour [7, 17, 18]. Collectively, Th1, Th2, and Th17 
cells are generally proinflammatory cells that elicit immune responses potentially 
favouring anti-tumour immunity.  
Interestingly, some studies have shown that CD4+ T cells can even develop direct cytotoxic 
activity against tumour cells [9, 19, 20].  In a study of melanoma, the transfer of naïve, 
tumour-reactive CD4+ T cells into lymphocyte-depleted mice resulted in tumour rejection, 
which was further enhanced by CTLA-4 blockade. This tumour rejection was found to be 
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the result of acquired cytotoxic CD4+ T cell activity, directly targeting tumour cells 
presenting antigens on MHC class II molecules. These cytotoxic CD4+ T cells were 
proposed to function like CD8+ T cells, using granzyme-containing granules to cause 
tumour cell death [19]. 
In contrast, regulatory T cells (Tregs) are a subset of CD4+ T cells that tend to be associated 
with anti-inflammatory and immunosuppressive responses [21]. Tregs, responding to 
chemokines, can be recruited to the tumour and suppress immune cells by producing 
immunosuppressive cytokines and metabolites, inhibiting APC function, using checkpoint 
molecules to impair cytotoxic T cell function, and killing effector T cells [21]. 
Cumulatively, these effects drastically hinder the elimination of tumours, and studies have 
established that high Treg:CD8 ratios in tumours are associated with poorer patient survival 
[7]. Therefore, the role of CD4+ T cells in anti-tumour immunity can be variable and may 
depend on the CD4 subtype and the context of the tumour microenvironment. 
1.2.3 NK cells 
NK cells are a component of the innate immune system and are lymphoid cells that lack 
surface T cell receptors or antigen-specific receptors [22]. They are known to kill virally 
infected cells and tumour cells via NK cell-mediated cytotoxicity and cytokine production. 
Sharing similar functions with CD8+ T cells, NK cells utilize perforin and granzyme to kill 
infected cells, as well as employing TRAIL to target tumour cells [5]. In addition, NK cells 
produce IFN- γ, which promotes the function of some innate cells and may directly inhibit 
tumour growth [11], as previously mentioned. In contrast, specific to NK cell function, NK 
cells can recognize and kill abnormal cells without the need for prior activation [23]. The 
‘missing self’ hypothesis states that healthy cells will express self-MHC class I molecules, 
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while abnormal cells, including some tumour cells, lack the expression of self-MHC 
molecules. These abnormal cells are subsequently detected and eradicated by NK cells 
[24]. However, some tumour cells expressing self-MHC molecules can still be cleared by 
NK cells, while erythrocytes, lacking in self-MHC-expression, can avoid NK cell killing. 
This suggests that the activation or inhibition of NK cell activity is not dependent solely 
on self-MHC expression or a single induction signal. Rather, NK cell activity relies on, and 
is dictated by, a sum of activation and inhibition signals mediated by different cell surface 
receptors [23]. Of note, the infiltration of NK cells in solid tumours is associated with an 
improved prognosis in patients [25]. Thus, NK cells are a crucial component in tumour 
immunosurveillance. 
1.2.4 iNKT cells 
iNKT cells are a subset of T cells that share characteristics of both NK cells and T cells, 
thus they are considered to bridge innate and adaptive immunity [8]. Along with various 
NK cell surface molecules, iNKT cells express invariant T cell receptors that recognize a 
diverse range of lipid antigens in a CD1d-restricted manner. Recognition of lipid antigens 
by iNKT cells results in the production of immunostimulatory cytokines, which enhances 
the ability of other immune cells, such as APCs, B cells, and T cells, to detect and eradicate 
tumours. iNKT cells can be activated directly by some CD1d-expressing tumour cells 
presenting lipid antigens. Alternatively, activation of iNKT cells occurs via presentation of 
tumour lipids by APCs [26, 27]. More importantly, human iNKT cells have been shown to 
have cytotoxic effects against CD1d-expressing osteosarcoma tumours [26, 28]. 
Osteosarcoma cells expressing CD1d were effectively recognized and killed by iNKT cells, 
whereas osteosarcoma cells without CD1d expression were not eliminated [26, 28]. In 
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addition, a model of murine breast cancer showed that the downregulation of CD1d 
expression by tumour cells inhibited iNKT cell-mediated killing and promoted metastases 
[26, 29]. These data demonstrate the importance of iNKT cells in anti-tumour immunity. 
1.2.5 B cells 
Finally, the role of B cells in cancer has been widely disputed due to their dual effects on 
promoting and inhibiting anti-tumour immune responses [4]. Antibodies produced by 
plasma cells, which are derived from B cells, can recognize tumour antigens to induce 
complement-mediated tumour killing, Fc-mediated phagocytosis, and antibody-dependent 
cell-mediated cytotoxicity [4]. These mechanisms promote the recognition of tumours by 
phagocytes and NK cells. Additionally, B cells function as APCs, serving to activate T 
cells and potentially bolstering anti-cancer responses. Of clinical relevance, the presence 
of B cells in tumour infiltrates have been correlated with improved patient survival in some 
tumours [4]. However, B cells have also been shown to suppress immune responses. 
Antibodies bound to antigens can form immune complexes, which induce the production 
of myeloid-derived suppressor cells (MDSCs), leading to inhibition of CD4+ and CD8+ T 
cell activity [4, 30-32]. A subset of B cells, regulatory B cells (Bregs), are 
immunomodulatory cells critical for regulating immune homeostasis. Bregs produce a 
variety of cytokines, including IL-10 and TGF-β to inhibit proinflammatory cells and 
promote the generation of Tregs, MDSCs, and other immunosuppressive cells [4, 30-32]. 
It has been shown that using IL-10, Bregs suppressed inflammation in models of colitis, 
arthritis, and experimental autoimmune encephalomyelitis [33-36]. More importantly, it 
was reported that IL-10 production by Bregs can suppress the phagocytic capacity of 
macrophages and promote tumour progression [31, 37, 38]. Additionally, in a murine 
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model of breast cancer, anti-CD20 was used to deplete B cells. Since Bregs express low 
levels of CD20, Bregs were not depleted and tumour metastasis was paradoxically 
enhanced in this study [31, 37, 39]. Thus, while B cells can promote tumour killing by 
serving as APCs to activate tumour-specific T cells, some subsets (e.g. Bregs) can  be 
detrimental to anti-tumour responses. 
1.3 Immunoediting and Immune Evasion 
While the immune system may seem efficient at detecting and eradicating tumours 
(immunosurveillance), one of the fundamental hallmarks of cancer is the ability to evade 
the immune system [2]. It can be argued that a tumour cannot exist without the ability to 
evade the host immune response. This involves the concept of immunoediting, which 
describes immunosurveillance and cancer progression via three phases – elimination, 
equilibrium, and escape [40, 41]. The elimination phase requires immune cells to 
successfully detect and eradicate tumour cells completely. Equilibrium describes a phase 
of dormancy, where there is a balance between tumour elimination and tumour progression. 
While the immune system remains active to kill tumour cells, tumour elimination is not 
complete. In the equilibrium phase, the immune system essentially selects for tumour cells 
with the ability to avoid immune detection and elimination. However, tumour cells can be 
maintained in the equilibrium phase for long periods of time. Some tumour cells can no 
longer be controlled or maintained by the immune system and enters the escape phase, 
where tumours are clinically detectable [40, 41].  
In order to escape the immune system, tumour cells frequently inhibit the host lymphocytes 
that directly mediate or regulate anti-tumour immunity, including T cells, NK cells, and 
iNKT cells [42]. For instance, tumours create an immunosuppressive microenvironment to 
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evade the immune system by recruiting regulatory T cells, regulatory B cells, and myeloid-
derived suppressor cells, stimulating the production of immunosuppressive cytokines (eg. 
IL-10 and TGF-β), and/or expressing immune checkpoint molecules to inhibit activated 
lymphocytes [43-45]. Immune checkpoint molecules are normally expressed by immune 
cells to suppress and regulate immune responses. However, some tumour cells exploit this 
mechanism and use immune checkpoint molecules to evade the immune system [46]. In 
the past few years, dramatic improvements in anti-cancer therapies have arisen due to the 
discovery of checkpoint inhibitors (eg. Nivolumab) that serve to block these immune 
evasion pathways. However, despite their effectiveness, only a small fraction of patients 
respond to them [47]. Therefore, discovering novel mechanisms of anti-cancer immunity 
will be crucial to developing future cancer therapies. 
1.4 T cell immunoglobulin and mucin domain-1 (Tim-1) 
Tim-1 is a type I transmembrane glycoprotein [48, 49] that is expressed in a variety of cell 
types in the host, including both immune cells and parenchymal cells. Tim-1 functions as 
a receptor for ligands such as Tim-4 and phosphatidylserine (PS), with Tim-4 being 
predominantly expressed on APCs and PS expressed on early apoptotic cells [50, 51]. In 
addition, Tim-1 functions as a receptor for Hepatitis A virus, hence, its gene is also referred 
to as Hepatitis A Virus Receptor 1 (HAVCR1) [52, 53].  
In the kidney, Tim-1 is referred to as kidney injury molecule-1 (Kim-1) and is highly 
upregulated on proximal tubular epithelial cells (PTECs) during acute kidney injury [48]. 
Tim-1 is a receptor for phosphatidylserine (PS), which functions as an “eat me” signal on 
apoptotic and necrotic cells, and Tim-1 ligation induces PTECs to phagocytose apoptotic 
and necrotic cells [49, 54, 55]. This process aids in the clearance of dying cells and reduces 
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inflammation [56], which has been shown to promote tissue repair. Mice transplanted with 
syngeneic Tim-1-expressing donor kidneys exhibited improved graft outcome and greater 
survival compared to mice receiving Tim-1-deficient donor kidneys, demonstrating the 
importance of Tim-1 expression in renal repair during transplantation [57, 58].  
1.5 Tim-1 in the Immune System 
In the immune system, lymphocytes expressing Tim-1 include CD4+ T cells, iNKT cells, 
and Bregs [59-62]. The TIM gene family was originally discovered in a mouse model of 
asthma, where Tim-1 expression on T cells was shown to influence the regulation of atopic 
diseases such as asthma. Some TIM-1 polymorphisms in humans were also associated with 
an increased risk of asthma [63, 64]. Protection against atopy in humans was associated 
with prior infection with Hepatitis A virus, the receptor for which is encoded by the Tim-
1 gene, HAVCR1 [52, 65]. This finding was essential in supporting the hygiene hypothesis, 
which states that the increase of allergic and autoimmune diseases is correlated to the 
decrease of infectious diseases [66, 67].  
Tim-1 expression is upregulated on CD4+ T cells following T cell receptor (TCR) 
engagement by cognate peptide-MHC interactions on APCs and functions as a 
costimulatory molecule [52, 68]. Interaction between Tim-1 on activated CD4+ T cells and 
Tim-4 on APCs can promote T cell activation, proliferation, and cytokine production [50, 
69, 70]. Tim-1 is preferentially expressed by Th2 cells, compared to Th1 and Th17 cells 
[59, 69, 71-73]. Moreover, Tim-1 has been implicated in promoting the trafficking of Th1 
and Th17 cells [74]. P-selectin, an adhesion molecule expressed on the surface of activated 
endothelial cells, is a potential ligand for Tim-1 and can mediate the rolling and tethering 
of lymphocytes via Tim-1. Th1 and Th17 cells expressing Tim-1 with a deficient mucin 
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domain exhibited reduced tethering and adherence to P-selectin. In a contact 
hypersensitivity model, mice with Th1 cells that have mucin domain-deficient Tim-1 were 
observed to experience a decreased recruitment of Th1 cells to inflamed skin [74]. In 
addition, mice with Th1 cells that express mucin domain-deficient Tim-1 exhibited 
decreased severity of experimental autoimmune encephalomyelitis [74].Therefore, the 
expression of Tim-1 could theoretically enhance anti-tumour immunity by inducing the 
activation of CD4+ T cells, which can subsequently promote inflammatory responses, 
improve lymphocyte trafficking, and lead to increased CD8+ T cell activation. 
Tim-1 is constitutively expressed on iNKT cells and binds PS present on apoptotic cells 
[75]. This interaction not only leads to iNKT cell activation, proliferation, and cytokine 
production, but the ligation of PS to Tim-1 on pulmonary iNKT cells can induce airway 
hyperreactivity, which is a critical feature of asthma [75]. More importantly, iNKT cells 
have been implicated in promoting an anti-tumour immune response [26]. Studies have 
shown that mice deficient in iNKT cells exhibit greater tumour growth [76, 77], and in a 
variety of solid malignancies in humans, diminished iNKT cell function and cell number 
was observed [78-80]. Notably, iNKT cells can directly kill tumour cells by secreting 
perforin and granzyme [81], and activation of iNKT cells promotes the induction of CD4+ 
T cell, CD8+ T cell, and NK cell anti-tumour responses [82-84]. 
Tim-1 expression is upregulated on B cells upon B cell receptor signalling, and Tim-1 
subsequently interacts with PS on apoptotic cells [85]. This leads to B cells differentiating 
into IL-10-producing Bregs, which are essential for regulating and suppressing immune 
responses [85, 86]. It has been postulated that Tim-1 is predominantly expressed by B cells, 
rather than T cells, with approximately 70% of IL-10-producing Bregs expressing Tim-1 
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[87, 88]. Tim-1 expression on B cells can be induced using anti-IgM in vitro, which 
suggests that Tim-1 expression on B cells is dependent on B cell receptor signalling [62]. 
It has been shown that mice lacking Tim-1 have a dramatic reduction in the number of IL-
10-producing Bregs, which leads to T cell hyper-responsiveness and susceptibility to 
rejection in cardiac transplantation [85]. In addition, separate studies have demonstrated 
that the adoptive transfer of Tim-1-expressing Bregs prolonged allograft survival of islet 
transplants [87] and reduced the severity of experimental autoimmune encephalomyelitis 
[86]. More importantly, Ding et al. demonstrated accelerated tumour growth in B cell-
deficient mice inoculated subcutaneously with B16F10 melanoma and receiving a transfer 
of syngeneic Tim-1-expressing B cells from B16F10 immunized mice [89]. These findings 
further suggest that the role of Tim-1 expression on Bregs is immunosuppressive and may 
potentially inhibit anti-tumour immune responses, but this has not yet been well studied.  
Although the versatile role of Tim-1 has been established in parenchymal and immune 
cells, the potential role of Tim-1 on anti-tumour immunity is not yet known. 
1.6 RATIONALE AND HYPOTHESIS 
In this study, the murine tumour models, B16 melanoma and MC38 colorectal 
adenocarcinoma were used to study anti-cancer immune responses. They are widely used 
in tumour studies, grow well as a subcutaneous tumour, and are variably immunogenic 
(able to induce an immune response) [90-92]. Thus, these tumours can be readily 
monitored, and immune responses can be analyzed.  
B16 melanoma is a spontaneously derived C57BL/6 cell line, commonly used to study 
malignant melanoma, its metastatic properties, and various treatment options. Several 
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variants of B16 melanoma are commercially available, including B16F1 (parental), B16F0 
(non-metastatic), and B16F10 (highly metastatic) [90]. In this study, the parental line, 
B16F1, will be used to investigate anti-tumour immunity in the absence of metastases.  
To further support my findings, tumour growth and survival using MC38 colorectal 
adenocarcinoma were studied. MC38 colorectal adenocarcinoma was derived from a 
chemically induced adenocarcinoma in a C57BL/6 mouse, and has been shown to be 
moderately immunogenic [93]. These murine tumour models were implemented to test the 
robustness of my hypothesis and to test the ability to generalize my findings to other 
cancers. 
Since the expression of Tim-1 affects the activation and/or function of CD4+ T cells, iNKT 
cells, and Bregs in various capacities, I hypothesized that the proinflammatory responses 
of CD4+ T cells and iNKT cells induced by Tim-1 would exceed the immunosuppressive 
effects of Tim-1-expressing Bregs. I expected to observe decreased tumour growth and 
improved survival in Tim-1-expressing mice inoculated with subcutaneous tumours, 





2 MATERIALS AND METHODS 
2.1 Mice 
Male, 8-10 week old, wild-type (Tim-1-expressing) C57BL/6 (B6; H-2b) mice were 
purchased from the Charles River Laboratory. Tim-1-deficient C57BL/6 mice were 
generated and generously provided by Dr. Andrew N.J. McKenzie (MRC laboratory of 
Molecular Biology, Cambridge, UK). Tim-1-deficient mice were generated by targeted 
disruption of the mouse Tim-1 (HAVCR1-/-) gene in mouse embryonic stem cells, with no 
change in the overall phenotype compared to wild-type C57BL/6 mice [62]. The Tim-1-
deficient genotype was confirmed by Dr. Xizhong Zhang (Gunaratnam lab) using PCR 
genotyping. Mice were maintained in the Animal Care and Veterinary Services facility at 
the University of Western Ontario (UWO) and food and water were provided ad libitum. 
All animal protocols were approved by the Animal Care Committee at UWO (Protocol 
number: 2018-147) (Appendix A). 
2.2 Murine Tumour Cell Culture 
B16F1 melanoma cells were purchased from the American Type Culture Collection 
(Manassas, Virginia, USA). Cells were cultured in Roswell Park Memorial Institute (RPMI 
1640) medium supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (P/S) (Thermo Fisher Scientific).  
MC38 colorectal adenocarcinoma cells were generously provided by Dr. James 
Koropatnick (The University of Western Ontario). Cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% FBS and 1% P/S. 
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Unless otherwise stated, all cell lines were cultured at 37ºC and 5% CO2. All cell lines were 
washed with 1x PBS and passaged for a maximum of 10 times using 0.25% trypsin (Life 
Technologies). 
2.3 Subcutaneous Tumour Models 
8-10 week old, male, Tim-1-expressing and Tim-1-deficient C57BL/6 mice were 
anesthetized with isoflurane and subcutaneously injected in the right flanks with B16F1 
melanoma (5x105 cells), MC38 colorectal adenocarcinoma (1x105 cells), or B16F10-OVA 
melanoma (5x105 cells) in 100ul of Hanks’ Balanced Salt Solution (HBSS). Tumours were 
measured with calipers and tumour volume was calculated with the formula: mm3=(length 
x width2)/2. Endpoints were determined by incidence of cachexia, tumour ulceration, or 
tumour diameter exceeding 10mm, as per standard operating procedures of the Animal 
Care and Veterinary Services at UWO. 
2.4 Histology 
Excised tumours were washed with 1X PBS and fixed in 10% neutral buffered formalin 
for 48 hours. Fixed samples were sent to a laboratory technician (Weihua Liu from the 
Department of Pathology and Laboratory Medicine at UWO) for paraffin embedding and 
staining with Hematoxylin & Eosin (H&E). Stained tumour sections were analyzed by a 
pathologist (Dr. Manal Gabril, MD, MSc, FRCPC) in a blinded fashion and percent 
necrosis was scored using Suzuki’s histological criteria [94]. Suzuki’s criteria scores 
necrosis as a percentage, ranging from none (0%), minimal (single-cell necrosis), mild (< 
30%), moderate (30-60%), to severe (> 60%).   
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2.5 Isolation of Splenocytes 
Excised spleens were washed with 1X PBS and mechanically homogenized through a 
40um cell strainer (Fisher Scientific) in 1X PBS. The cell suspensions were centrifuged 
(Thermo Scientific Medifuge Benchtop Centrifuge) at 500rcf for 5 minutes at 4°C and 
resuspended with 1ml of ACK lysis buffer for each spleen for 1 minute. Splenocytes were 
washed twice with 1X PBS. For flow cytometry, splenocytes were cryopreserved in 90% 
FBS and 10% DMSO at -80°C, and when needed, cryopreserved splenocytes were rapidly 
thawed in RPMI media (with 10% FBS) at 37°C.  
2.6 Immunization with Heat-Killed B16F1 Melanoma 
B16F1 melanoma cells (5x106 cells/ml) suspended in 1X PBS were heat-killed in a water 
bath at 65°C for 20 minutes. Heat-killed cells were kept on ice until injections were 
performed. Mice were anesthetized using isoflurane and 5x105 heat-killed B16F1 
melanoma cells were subcutaneously injected into the right flanks of Tim-1-expressing and 
Tim-1-deficient mice. Mice were euthanized on day 7 post-immunization and splenocytes 
were isolated and process as described above.  
2.7 Flow Cytometry 
All staining procedures were performed in 1X PBS with 2% FBS at 4°C. To block non-
specific binding, single-cell suspensions were incubated with Purified Rat Anti-Mouse 
CD16/CD32 (BD Biosciences) for 10 minutes. Without washing, cell surface markers were 
stained by incubating with fluorochrome-conjugated antibodies for 30 minutes and 
resuspended in 1xPBS with 2% FBS. Intracellular staining was performed using the 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Fluorochrome-conjugated 
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antibodies used in this study can be found in Table 1. Negative controls were established 
using isotype-matched controls. Cells were analyzed on a CytoFLEX S flow cytometer 





Table 1. Antibodies used for flow cytometry 
Antibody Fluorochrome Clone Source 
Anti-mouse TCR-β BV605 H57-597 BioLegend 
Anti-mouse CD8a PE-Cy7 53-6.7 eBioscience 
Anti-mouse CD4 BV421 GK1.5 BioLegend 
Anti-mouse CD279 (PD-1) APC RMP1-30 eBioscience 
Anti-mouse T-bet APC 4B10 BioLegend 
Anti-mouse GATA3 APC 16E10A23 BioLegend 
Anti-mouse FOXP3 APC FJK-16s eBioscience 
Anti-mouse NK1.1 APC PK136 eBioscience 
Anti-mouse CD19 APC 6D5 BioLegend 
Anti-mouse CD1d PE-Cy7 1B1 BioLegend 
Anti-mouse CD5 BV421 53-7.3 BioLegend 
Anti-mouse CD11b FITC M1/70 BioLegend 
Anti-mouse Ly-6C BV605 HK1.4 BioLegend 






2.8 IncuCyte Immune Cell Killing Assay 
On day 0, B16F1 melanoma cells were seeded (1000, 2000, or 3000 cells in 100ul of RPMI 
media + 10% FBS + 1% P/S per well) into a 96-well flat bottom plate (Corning 3595) to 
achieve a cell confluency of ~20% on day 1. On day 1, media was gently removed from 
each well. To each well, 100nM of Sytox Green Nucleic Acid Stain (Thermofisher) and 
effector cells (splenocytes from Tim-1-expressing or Tim-1-deficient mice) in DMEM 
were added to achieve a total assay volume of 200ul. Two target-to-effector cell ratios were 
used (1:5 and 1:10). Negative controls received no effector cells (media only) and positive 
controls received 1% Triton X-100 (Sigma Aldrich). The assay plate was placed into the 
IncuCyte Live-Cell Analysis System (Essen Bioscience) to be incubated at 37ºC and 5% 
CO2 and fluorescent images of each well were taken hourly at 4x magnification for 24 
hours. 
2.9 In vivo RMT1-10 Treatment 
Anti-mouse Tim-1 (RMT1-10; Bio X Cell) or control rat IgG2a (Bio X Cell) was 
administered intraperitoneally at 300ug in InVivoPure pH 7.0 Dilution Buffer (Bio X Cell) 
on days −1, 0, and every 3 days relative to the day of subcutaneous tumour injections.  
2.10 Statistical Analyses 
Statistical analyses used a log-rank (Mantel Cox) test, a repeated measures ANOVA, a 
Mann-Whitney test, or an unpaired two-tailed Student’s t-test, as indicated. Differences 






3.1 Delayed B16F1 melanoma tumour growth and improved survival in Tim-
1-deficient mice 
I aimed to investigate tumour growth and survival in Tim-1-deficient and Tim-1-expressing 
(wild-type) C57BL/6 mice using the syngeneic B16F1 melanoma cell line.  Mice received 
a subcutaneous inoculation of 5x105 B16F1 melanoma cells and were weighed, monitored 
for cachexia, and tumour growth was measured using calipers over time. While I initially 
hypothesized poorer outcomes in Tim-1-deficient mice, I observed improved survival and 
delayed tumour growth in Tim-1-deficient mice, compared to wild-type, Tim-1-expressing 
mice (Figure 1A and 1B). Upon repeating the experiment, I confirmed the original findings, 
as similar results were observed (Figure 1C and 1D). Tim-1-deficient mice exhibited 
improved survival and delayed tumour growth, compared to Tim-1-expressing mice 
(Figure 1C and 1D). Spider plots depicting tumour growth from individual mice are shown 
in Supplementary Figure 1A and 1B. These findings suggest that Tim-1 expression may 


















Figure 1. Delayed B16F1 melanoma tumour growth and improved survival in 
immunocompetent Tim-1-deficient mice. 
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Tim-1-expressing and Tim-1-deficient male C57BL/6 mice at 8-10 weeks old were 
subcutaneously inoculated with 5x105 B16F1 melanoma. Endpoints were determined by 
incidence of cachexia, tumour ulceration, or a mean tumour diameter exceeding 10mm. 
(A) Survival curve (Mantel-Cox test, **p=0.0047) and (B) tumour size (mm3) of inoculated 
Tim-1-expressing (n=4) and Tim-1-deficient (n=5) mice (Repeated Measures ANOVA, 
****p<0.0001). In a repeated experiment, (C) survival curve (Mantel-Cox test, 
**p=0.0052) and (D) tumour size (mm3) of inoculated Tim-1-expressing (n=5) and Tim-1-
deficient (n=4) mice (Repeated Measures ANOVA, ****p<0.0001).   
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3.2 Reduced levels of tumour necrosis in Tim-1-deficient mice 
Tumour necrosis in biopsy specimen from patients with melanoma is considered to be a 
poor prognostic factor [95]. To examine the levels of necrosis within the implanted B16F1 
melanoma tumours, tumours were excised when they reached a diameter of ~10mm. The 
tumours were fixed in 10% formalin, embedded in paraffin, and sectioned before staining 
with H&E to observe necrosis. Healthy, viable tumour cells are stained purple with a large, 
visible nuclei and have a defined cell shape. In contrast, necrotic tumour cells are stained 
pink with a loss of nuclei [96-98]. Another population of cells with a darker nucleus was 
noted by the pathologist to potentially be infiltrating lymphocytes, which warrants further 
study to determine the phenotype of these cells using immunohistochemistry (Figure 2A). 
The percent necrosis was scored by a pathologist and it was observed that tumours in Tim-
1-expressing mice exhibited greater levels of necrosis, compared to tumours in Tim-1-










Figure 2. Reduced necrosis in tumours of Tim-1-deficient mice. 
B16F1 melanoma tumours were excised from Tim-1-expressing and Tim-1-deficient mice 
at their endpoints. Tumours were fixed in 10% neutral buffered formalin and embedded in 
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paraffin before sectioning and staining with H&E. (A) Tumour sections from Tim-1-
expressing and Tim-1-deficient mice are shown at 20x magnification. Scale bar = 100 
microns. Areas of necrosis, viable tumour tissue, and suspected TILs are as labelled. (B) 
Percent necrosis as scored by a pathologist (Mann-Whitney, *p=0.0476).  
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3.3 In vitro T cell killing of B16F1 melanoma cells 
Using the IncuCyte Live Cell Imaging System, I sought to assess in vitro T cell killing of 
B16F1 melanoma cells. From tumour-bearing mice, I isolated Tim-1-deficient and Tim-1-
expressing splenocytes as effector cells for coculture with the adherent B16F1 melanoma 
cell line. Graphs were generated using the IncuCyte software to depict the events of green 
fluorescence (ie. cell death) over time.  
Although statistical analyses could not be performed due to the low number of replicates, 
there did not seem to be any differences in tumour cell death between cocultures using 
Tim-1-expressing or Tim-1-deficient effector cells (Figure 3A). However, upon analysis 
of the images taken by the IncuCyte software, I observed that both tumour cells and effector 
cells were undergoing cell death and took up the Sytox green nucleic acid stain (Figure 
3B). This caused cell death between target and effector cells to be indistinguishable. In 
addition, some graphs generated by the IncuCyte software appeared inconsistent and erratic 
(Figure 3A). Therefore, the immune cell killing of tumour cells between Tim-1-expressing 
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Figure 3. IncuCyte immune cell killing assay. 
B16F1 melanoma target cells were seeded into a 96-well plate at various seeding densities 
(1000, 2000, and 3000 cells/well). Splenocytes were isolated from the spleens of tumour-
bearing Tim-1-expressing and Tim-1-deficient C57BL/6 mice. Splenocytes were added to 
each well at various target to effector ratios (1:5 and 1:10). 100nm of Sytox green nucleic 
acid stain was added to each well to visualize cell death. Cocultures were incubated at 37ºC 
and 5% CO2 for 24 hours, and images were taken hourly by the IncuCyte software. (A) 
Representative graphs of various cocultures generated by the IncuCyte software, depicting 
green fluorescent events (cell death) over time. (B) Representative image of a coculture 





3.4 Decreased frequencies of Bregs in Tim-1-deficient mice immunized with 
B16F1 melanoma  
To obtain insight into the host’s immune response elicited against B16F1 melanoma, I 
analyzed immune cell frequencies in the spleen of tumour-bearing mice. At their endpoints, 
the tumour-bearing mice were euthanized, and splenocytes were isolated and stained for 
multi-colour flow cytometric analysis. The gating strategy used and the analysis of the 
immune cells are shown in Figure 4A and 4B. 
I examined the frequencies of CD8+ T cells, CD4+ T cells – Th1 cells, Th2 cells, and 
Tregs, NK cells, NKT cells, Bregs, and myeloid cells that include monocytic MDSCs and 
granulocytic MDSCs between Tim-1-expressing and Tim-1-deficient mice. Unexpectedly, 
I did not observe any differences in the frequency of these immune cell populations 
between Tim-1-expressing and Tim-1-deficient mice (Figure 4C).  
In order to stimulate an immune response against the tumour cells, I opted to immunize the 
Tim-1-expressing and Tim-1-deficient mice by subcutaneously injecting the mice with 
heat-killed (necrotic) B16F1 melanoma cells. Immunized mice were euthanized 7 days 
post-immunization, and splenocytes were isolated and stained for flow cytometric analysis 
as previously performed. I observed decreased frequencies of Bregs and myeloid cells with 
a phenotype consistent with monocytic MDSCs in the immunized Tim-1-deficient mice 
(Figure 4D). However, there were no significant differences in the frequency of other 
immune cell populations between the immunized Tim-1-expressing and Tim-1-deficient 
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mice (Figure 4D). These findings suggest that Tim-1 expression may promote tumour 































Figure 4. Decreased frequencies of Bregs in Tim-1-deficient mice immunized with 
necrotic B16F1 melanoma cells.  
Splenocytes were isolated from B16F1 melanoma tumour-bearing Tim-1-expressing and 
Tim-1-deficient mice at their endpoints. Splenocytes were stained with fluorochrome-
conjugated antibodies for analysis using flow cytometry. (A) Gating strategy for 
extracellular staining of NK cells and NKT cells. (B) Gating strategy for intracellular 
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staining of Tregs. (C) Frequency of immune cell populations in splenocytes of Tim-1-
expressing (n=3) and Tim-1-deficient (n=3) mice (unpaired t-test). To induce an immune 
response, Tim-1-expressing and Tim-1-deficient mice were subcutaneously immunized 
with heat-killed B16F1 melanoma, and splenocytes were isolated 7 days post-
immunization. (D) Frequency of immune cell populations in splenocytes of immunized 




3.5 Effect of anti-Tim-1 monoclonal antibody, RMT1-10, on immune 
responses against B16F1 melanoma 
To test the effects of Tim-1 signalling in anti-tumour immune responses in vivo, I used the 
anti-Tim-1 mAb RMT1-10 to activate Tim-1 on immune cells. RMT1-10 is a low affinity 
anti-Tim-1 mAb that has been shown to induce the expansion of Tim-1-expressing Bregs 
[87]. RMT1-10 has been used in different murine models to reduce the severity of 
experimental autoimmune encephalomyelitis [99] and promote cardiac allograft tolerance 
at the doses used  [100]. These data taken together further support the claim that RMT1-10 
promotes Breg production. 
I administered 300ug of RMT1-10 or 300ug of the isotype control intraperitoneally to Tim-
1-expressing mice. Subsequently, mice were subcutaneously inoculated with 5x105 B16F1 
melanoma cells.  I continued to administer either 300ug of RMT1-10 or 300ug of the 
isotype control to the respective mice every 3 days subsequent to tumour inoculation. I 
observed a slight trend of earlier tumour growth and poorer survival in mice receiving 
RMT1-10, compared to the mice receiving the isotype control (Figure 5A and 5B). Spider 
plots depicting tumour growth from individual mice are shown in Appendix B. However, 
these findings were not statistically significant. Further studies with an increased sample 








Figure 5. Effect of anti-Tim-1 monoclonal antibody, RMT1-10, on B16F1 melanoma 
tumour growth and survival in Tim-1-expressing mice. 
Tim-1-expressing mice received either 300ug of RMT1-10 (n=8) or 300ug of IgG control 
(n=7) intraperitoneally on days -1, 0, and every 3 days relative to subcutaneous B16F1 
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melanoma administration. Endpoints were determined by incidence of cachexia, tumour 
ulceration, or a mean tumour diameter exceeding 10mm. (A) Percent survival (Mantel-Cox 
test) and (B) tumour size (mm3) of inoculated Tim-1-expressing mice treated with either 
RMT1-10 or IgG control (Repeated Measures ANOVA).   
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3.6 Effect of MC38 colorectal adenocarcinoma in Tim-1-expressing and Tim-
1-deficient mice 
Finally, in order to determine if the delayed tumour growth and improved survival observed 
in Tim-1-deficient mice inoculated with B16F1 melanoma were generalizable to other 
tumour cell lines, I tested tumour growth and survival using MC38 colorectal 
adenocarcinoma. Similar to the B16F1 melanoma cell line, MC38 colorectal 
adenocarcinoma is syngeneic to C57BL/6 mice. Tim-1-expressing and Tim-1-deficient 
mice were anesthetized using isoflurane and subcutaneously inoculated with 1x105 MC38 
colorectal adenocarcinoma cells. Consistent with the findings using B16F1 melanoma, 
Tim-1-deficient mice exhibited delayed tumour growth (Figure 6A). There were no 
significant differences in the survival between Tim-1-expressing and Tim-1-deficient mice 
(Figure 6B). However, when this experiment was repeated with additional mice in each 
group, no significant differences were observed in tumour growth and survival (Figure 6C 
and 6D). Spider plots depicting tumour growth from individual mice are shown in 
Supplementary Figure 3A and 3B. This potentially indicates that the effects of Tim-1 on 


















Figure 6. Effect of MC38 colorectal adenocarcinoma on Tim-1-expressing and Tim-
1-deficient mice. 
Tim-1-expressing and Tim-1-deficient male C57BL/6 mice at 8-10 weeks old were 
subcutaneously inoculated with 1x105 MC38 colorectal adenocarcinoma. Endpoints were 
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determined by incidence of cachexia, tumour ulceration, or a mean tumour diameter 
exceeding 10mm. (A) Percent survival (Mantel-Cox test) and (B) tumour size (mm3) of 
inoculated Tim-1-expressing (n=4) and Tim-1-deficient (n=4) mice (Repeated Measures 
ANOVA, ****p<0.0001). In a repeated experiment, (C) percent survival (Mantel-Cox test) 
and (D) tumour size (mm3) of inoculated Tim-1-expressing (n=9) and Tim-1-deficient 





4.1 Overview of study 
Tim-1 is a cell-surface glycoprotein expressed on a variety of immune cells. Tim-1-
expressing immune cells are implicated in allergy, asthma, autoimmune disease, and 
transplant tolerance. Through different mechanisms, Tim-1 can promote immune 
responses through T cells and iNKT cells or inhibit immune responses through Breg 
function [54-93]. However, the role of Tim-1 in anti-tumour immune responses has not 
been studied in detail.  
In this study, I examined the anti-cancer effects of Tim-1 in two mouse tumour models. I 
initially hypothesized that Tim-1-expressing mice would have an improved prognosis due 
to the induction of proinflammatory responses of CD4+ T cells and iNKT cells induce by 
Tim-1. Surprisingly, my findings have demonstrated that Tim-1-deficient mice exhibited 
delayed tumour growth and improved survival, compared to Tim-1-expressing mice. These 
findings were accompanied by reduced necrosis in the tumours of Tim-1-deficient mice, 
which is an indicator of improved prognosis in human melanoma [95]. In addition, reduced 
frequencies of Bregs were found in B16F1 melanoma-immunized Tim-1-deficient mice. 
These results suggest that Tim-1 expression in the immune system may be detrimental to 
anti-tumour immunity, potentially by inducing Bregs. Accordingly, I have revised my 
hypothesis, and I propose that Tim-1-expressing Bregs contribute to the inhibition of anti-
tumour immune responses against B16F1 melanoma. 
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In my immune cell killing assay using the IncuCyte Live Cell Imaging System, graphs 
generated by the IncuCyte software appeared inconsistent and erratic. Additionally, I 
observed cell death in both the tumour cells and effector cells, and cell death between the 
target and effector cells were indistinguishable. Thus, I was unable to compare the immune 
cell killing of tumour cells between Tim-1-expressing and Tim-1-deficient effector cells. 
The unexpected issue of effector cells undergoing cell death and taking up the nucleic acid 
stain potentially contributed to the inaccuracies of the graphs, but this can be rectified by 
further isolating T cells from splenocytes for use as effector cells and by implementing a 
red cytoplasmic dye to stain the target cells. These changes will ensure the ability to 
distinguish cell death between the target and effector cells, and potentially demonstrate 
reduced in vitro killing of B16F1 melanoma cells by T cells from Tim-1-expressing mice.  
Finally, when Tim-1-expressing and Tim-1-deficient mice were inoculated with syngeneic 
MC38 colorectal adenocarcinoma, I observed delayed tumour growth in the Tim-1-
deficient mice, while there were no significant differences in the survival between Tim-1-
expressing and Tim-1-deficient mice. Unexpectedly, when this experiment was repeated, 
there were no significant differences in tumour growth or survival. Due to the 
inconsistencies of these data, it will be necessary to repeat this experiment to confirm my 
findings. Nevertheless, this potentially suggests that the role of Tim-1 in anti-tumour 
immunity is a phenomenon that may be restricted to certain types of tumours. 
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4.2 Immune profiles of B16F1 melanoma and MC38 colorectal 
adenocarcinoma 
Since I observed inconsistent findings using B16F1 melanoma and MC38 colorectal 
adenocarcinoma, I postulated that the effects of Tim-1 on anti-tumour immunity may differ 
depending on the type of tumour and the immune response elicited.  
B16F1 melanoma was spontaneously derived, exhibits poor immunogenicity with low 
levels of immune cell infiltrates, and reduced susceptibility to cytotoxic T cell killing. This 
is due to its lack of MHC class I expression and chemokine production to recruit T cells 
and other immune cells [101, 102]. B16F10 melanoma cells, a highly metastatic B16 
melanoma cell line, expresses high levels of β-catenin and low levels of other chemokines 
[103]. In human melanoma, β-catenin signalling is correlated to the prevention of T cell 
infiltration into tumours and resistance to immune checkpoint inhibition therapy [104]. 
However, it is important to note that human melanoma is highly immunogenic [102, 105]. 
In addition, a study showed that B16 melanoma cells express high levels of CTLA-4, which 
is an inhibitory ligand to suppress the function of T cells. It was also shown that B16 
melanoma models were particularly resistant to immunotherapies, in contrast to other 
tumour models (eg. CT26 colon carcinoma, RENCA renal cell carcinoma, 4T1 mammary 
carcinoma) [102].  
MC38 colorectal adenocarcinoma is a carcinogen-induced murine tumour cell line and is 
moderately immunogenic [106]. Immune cell infiltrates within MC38 tumours in mice 
include CD8+ T cells and NK cells, with gene expression signatures suggesting that 
cytolytic activity occurs [106, 107]. However, immunosuppressive cells, such as Tregs and 
MDSCs, were also abundant [106, 107]. This data is further supported by the detection of 
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the chemokine, KC/GRO, which recruit MDSCs and neutrophils to the tumour [106]. In 
response to checkpoint inhibition therapies, the MC38 colorectal adenocarcinoma model 
was modestly responsive to checkpoint inhibition, in comparison to other highly responsive 
murine colon cancers (eg. CT26 colon carcinoma) [107].   
Due to the differences between B16F1 melanoma and MC38 colorectal adenocarcinoma, I 
speculate that the immune responses influenced by Tim-1 on these tumours may be 
dissimilar.  
4.3 Potential role of Tim-1-expressing Bregs in suppressing anti-tumour 
immunity 
My findings suggest that Tim-1 expression on Bregs may potentially impede anti-tumour 
immunity. Bregs secrete IL-10 and TGF-β, cytokines that suppress proinflammatory cells 
and promote the development and recruitment of Tregs, consequently suppressing anti-
tumour immune responses [31, 32]. In a study of murine breast cancer, it was demonstrated 
that tumour-evoked Bregs promote tumour growth and lung metastases [108]. This effect 
was indicated to be a result of Treg conversion from resting CD4+ T cells [32, 108]. In 
addition, tumour-evoked Bregs have been shown to play an important role in regulating 
the ability of MDSCs to promote metastases and immunosuppression [109]. This is 
consistent with my findings, where decreased frequencies of both Bregs and potential 
monocytic MDSCs were observed in the spleens of B16F1 melanoma-immunized Tim-1-
deficient mice.  
Since Tim-1 signalling induces Breg production/activation and Tim-1 is expressed by 
~70% of IL-10 producing Bregs [87], a possible therapeutic would aim to block Tim-1 
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signalling. My future objective would be to generate a monoclonal antibody to target Tim-
1 and inhibit activation/signalling. This therapeutic strategy could potentially reduce the 
immunosuppressive activity of Bregs and improve anti-cancer immune responses. 
4.4 Future studies 
Since I have established that Tim-1-deficient mice have a better prognosis against B16F1 
melanoma than Tim-1-expressing mice, it is necessary to determine if Tim-1-expressing 
Bregs are inhibiting anti-tumour immune responses. To achieve this, my next step would 
be to perform an adoptive transfer using isolated B cells from naive Tim-1-expressing 
mice, tumour-bearing Tim-1-expressing mice, or tumour-bearing Tim-1-deficient mice 
into naïve Tim-1-deficient recipients before tumour inoculation. I expect Tim-1-deficient 
recipients of Tim-1-expressing B cells will have accelerated tumour growth and decreased 
survival compared to Tim-1-deficient recipients of Tim-1-deficient B cells.  
To improve the in vitro T cell killing assay using the IncuCyte system, I would incorporate 
a Red IncuCyte CytoLight Rapid Dye (Sartorius) to selectively label target tumour cells. 
This will allow us to pinpoint cell death specifically on the target cells and exclude the 
effector lymphocytes. 
Alternatively, I can utilize MHC tetramers to analyze the antigen (tumour)-specific T cell 
response in vitro. MHC tetramers are complexes of 4 MHC molecules which are associated 
with a specific peptide and are bound to a fluorochrome for analysis using flow cytometry. 
I will inoculate Tim-1-expressing and Tim-1-deficient mice with B16F10 melanoma 
expressing the artificial neoantigen, ovalbumin, which will induce a T cell response against 
the tumour. Using MHC tetramers with an ovalbumin peptide, I can isolate splenocytes 
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from the tumour-inoculated mice and detect antigen (ovalbumin)-specific CD8+ cytotoxic 
T cells. 
4.5 Limitations 
My study has a number of limitations. Due to the nature of this study, I required the use of 
Tim-1-expressing (wild-type) and Tim-1-deficient (Tim-1-/-) mice. Currently, the 
Gunaratnam laboratory only has access to this model on a C57BL/6 genetic background, 
which limits the tumour models to cell lines derived from C57BL/6 mice. In future studies, 
I plan to test tumour models syngeneic to BALB/c mice, which will expand the types of 
cancers that can be examined and confirm my findings in different strains of mice.  
It has been shown that C57BL/6 mice are predisposed to developing a Th1 immune 
response, while BALB/c mice preferentially develop a Th2 immune response [114]. Since 
Tim-1 is preferentially expressed by Th2 cells over Th1 cells, my results may not 
accurately represent the effects of Tim-1 on host lymphocytes in anti-tumour immunity. 
However, this can be better examined when tumour models in Tim-1-expressing and Tim-
1-deficient BALB/c mice are implemented in the future. 
The mouse models used in this study were restricted to male mice, which do not accurately 
represent or account for the sex differences observed in the respective cancer. In the United 
States, the incidence and mortality rate of cancer were higher in men than women from 
2009 to 2013 [110]. Additionally, the differences in sex hormones between men and 
women (eg. testosterone and estrogen, respectively) can impact the development of certain 
cancers [111]. Studies have shown that historically, males are predominantly used in 
clinical trials, while females were excluded [112], and increased adverse drug reactions 
against anti-cancer therapeutics were observed more often in women than men [113]. As a 
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result, it is important to take the effect of sex differences in cancer into consideration and 
include studies using both males and females.  
In this study, I demonstrated that Tim-1-deficient mice immunized with heat-killed B16F1 
melanoma cells exhibited decreased frequencies of splenic Bregs and a myeloid population 
with potential monocytic MDSCs. While the cell-surface markers used in this study to 
identify monocytic MDSCs (CD11b+, Ly-6C+) provide an initial framework for 
characterizing MDSCs, additional markers can be implemented to characterize these cells 
in further detail [115]. To identify monocytic MDSCs, additional cell-surface markers 
including Gr-1mid and CD49d+ can be used [116], and additional markers to identify 
granulocytic MDSCs in further detail include Gr-1hi [116].  
In addition, the immune cells I have characterized in this study were restricted to 
splenocytes. In order to accurately examine anti-tumour immune responses, infiltrating 
lymphocytes into the tumour and immune cells in the tumour-draining lymph nodes should 
be examined. Moreover, only three mice were used to analyze the splenic immune cell 
frequencies between Tim-1-expressing and Tim-1-deficient mice, which may not be 
sufficient to confidently draw firm conclusions. Therefore, it will be necessary to perform 
additional experiments to investigate the populations of immune cells present in the tumour 
and lymph nodes of tumour-bearing and tumour-immunized Tim-1-expressing and Tim-1-
deficient mice. 
Lastly, while subcutaneous tumours can be easily observed and measured with minimal 
invasiveness, research has shown that the site of tumour inoculation can affect anti-tumour 
immune responses. In a study of immunotherapies for murine colon cancer, the immune 
microenvironment of a subcutaneous tumour differed significantly from an orthotopic 
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gastrointestinal tumour [117]. While the establishment of an orthotopic tumour graft via 
surgical procedure gives rise to excessive inflammation, these researchers developed a 
novel orthotopic model using endoscopy-guided microinjection of tumour cells to reduce 
inflammation. They found that the immune microenvironment of the subcutaneous tumour 
graft was comprised of lower levels of immune cell infiltrates in the tumour and increased 
immunosuppressive cells compared to the orthotopic graft [117]. However, for the 
purposes of my study and for the sake of simplicity, I focused on elucidating the effects of 
Tim-1 on immune responses against tumours. Despite using the subcutaneous injection 
model, comparisons of immune responses between Tim-1-expressing and Tim-1-deficient 
mice can still be made. Once I establish the role of Tim-1 in anti-tumour immunity and 
specific mechanisms of Tim-1 function, I can address any discrepancies between 
subcutaneous and orthotopic tumour administration in future studies.   
4.6 Conclusion  
Cancer remains a highly prevalent and deadly disorder. Although, novel immunotherapies 
and checkpoint inhibitors have shown some success in patients, only a fraction of patients 
respond to these therapies. In this study, my work has demonstrated that Tim-1-deficient 
mice have improved outcomes when inoculated with B16F1 melanoma tumours, compared 
to Tim-1-expressing mice. Tim-1-deficient mice exhibited improved survival, delayed 
tumour growth, reduced tumour necrosis, and reduced frequencies of splenic Bregs. With 
additional research, these findings may potentially lead to improved anti-cancer treatments 
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Supplementary Figure 1. Delayed B16F1 melanoma tumour growth and improved 
survival in immunocompetent Tim-1-deficient mice. 
Tim-1-expressing and Tim-1-deficient male C57BL/6 mice at 8-10 weeks old were 
subcutaneously inoculated with 5x105 B16F1 melanoma. Endpoints were determined by 
incidence of cachexia, tumour ulceration, or a mean tumour diameter exceeding 10mm. 
(A) Spider plots depicting tumour growth from individual mice. (B) Spider plots depicting 
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Supplementary Figure 2. Effect of anti-Tim-1 monoclonal antibody, RMT1-10, on 
B16F1 melanoma tumour growth and survival in Tim-1-expressing mice. 
Tim-1-expressing mice received either 300ug of RMT1-10 (n=8) or 300ug of IgG control 
(n=7) intraperitoneally on days -1, 0, and every 3 days relative to subcutaneous B16F1 
melanoma administration. Endpoints were determined by incidence of cachexia, tumour 
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ulceration, or a mean tumour diameter exceeding 10mm. (A) Spider plots depicting tumour 
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Supplementary Figure 3. Effect of MC38 colorectal adenocarcinoma on Tim-1-
expressing and Tim-1-deficient mice. 
Tim-1-expressing and Tim-1-deficient male C57BL/6 mice at 8-10 weeks old were 
subcutaneously inoculated with 1x105 MC38 colorectal adenocarcinoma. Endpoints were 
determined by incidence of cachexia, tumour ulceration, or a mean tumour diameter 
exceeding 10mm. (A) Spider plots depicting tumour growth from individual mice. (B) 
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